Publications by authors named "Jan Astermark"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

321

Total Likes

174

Extended Reach

2,076,946

Social Features

48
G
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
Adam Cuker, Kaan Kavakli, Laurent Frenzel, Jiaan-Der Wang, Jan Astermark, Monica H Cerqueira, Alfonso Iorio, Olga Katsarou-Fasouli, Robert Klamroth, Amy D Shapiro

N Engl J Med· September 2024

Videos about Article: user user

2 3 46 6 72

View All Article and Social Media Activity
H
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study.
Jan Astermark, Susanna Ranta, Linda Myrin-Westesson, Marianne Hoffmann, Sandrine Quere

Haemophilia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study.
Davide Matino, Laurent Frenzel, Ali Bulent Antmen, Jan Astermark, Monica H Cerqueira

Haemophilia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemophilia B: an illustrative review of current challenges and opportunities.
Cedric Hermans, Jan Astermark, Sonata Šaulytė Trakymienė, Víctor Jiménez-Yuste

Res Pract Thromb Haemost· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study.
Jan Astermark, Petra LeBeau, Anders Christensson, Stefan Lethagen, Erik Berntorp

Res Pract Thromb Haemost· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy.
Jan Astermark, Wolfgang Miesbach, Michiel Coppens, Sander Gielen, Jaap Twisk

Haemophilia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries-Comparisons to Matched Controls.
Katarina Steen Carlsson, Jan Astermark, Fariba Baghaei, Elisabeth Brodin, Eva Funding

Haemophilia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis.
Jan Astermark, Tyler W Buckner, Laurent Frenzel, Anthony J Hatswell, David Hinds

Expert Rev Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
Pratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, Jan Astermark, Gary Benson

Lancet Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal.
Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao

Haemophilia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease.
Mark W Skinner, Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny

Haemophilia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study).
Ragnhild J Måseide, Erik Berntorp, Jan Astermark, Anna Olsson, Maria Bruzelius

Res Pract Thromb Haemost· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease: Outcome data from the Swedish haemophilia registry.
Nadine G Andersson, Hannes Brange, Jan Astermark, Malin Axelsson, Fariba Baghaei

Haemophilia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions.
Jan Blatný, Jan Astermark, Cristina Catarino, Gerry Dolan, Karin Fijnvandraat

Ther Adv Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients.
Alexandros Arvanitakis, Caroline Jepsen, Nadine G Andersson, Fariba Baghaei, Jan Astermark

Haemophilia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, Jan Astermark, Michael Recht

Lancet Haematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study).
Ragnhild J Måseide, Erik Berntorp, Jan Astermark, Anna Olsson, Maria Bruzelius

Haemophilia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context.
Jan Astermark, Fariba Baghaei, Karin Strandberg, Petra Gabric Toplican, Maj Friberg Birkedal

Ther Adv Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.
Alexandros Arvanitakis, Pål Andre Holme, Erik Berntorp, Jan Astermark

Haemophilia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Jan Astermark, Tyler W Buckner, Laurent Frenzel, Anthony J Hatswell, Xiaojun You

Haemophilia· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: analysis of phase III trials using patient-reported outcomes.
Jan Astermark, Cédric Hermans, Monia Ezzalfani, Alaeddine Sidhom, Sylvaine Barbier

Ther Adv Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Factor XIII deficiency - not only a congenital bleeding disorder].
Ulf Schött, Jan Astermark, Anna Zdanowski, Karin Strandberg

Lakartidningen· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for shared decision management in previously untreated patients with hemophilia A or B.
Jan Astermark, Jan Blatný, Christoph Königs, Cédric Hermans, Victor Jiménez-Yuste

Ther Adv Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Steven W Pipe, Frank W G Leebeek, Michael Recht, Nigel S Key, Giancarlo Castaman, Jan Astermark

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study.
Katarina Steen Carlsson, Bent Winding, Jan Astermark, Fariba Baghaei, Elisabeth Brodin

Res Pract Thromb Haemost· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis